Stay updated on Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.

Latest updates to the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page
- Check2 days agoChange DetectedA new Sample Collection element was added to the study plan, and the record version was updated to v3.5.4, replacing the previous v3.5.3 revision.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision: v3.5.3 was added, replacing the previous v3.5.2. This indicates an administrative update to the page.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedNew page revision 3.5.2 was added on 2026-04-13 and an older revision 3.5.0 was removed on 2026-04-07. These entries reflect metadata about the page version rather than substantive updates to the study details.SummaryDifference0.1%

- Check37 days agoChange DetectedStudy record timeline updated: 2026-04-07 and 2026-04-08 were added, while 2026-04-01 and 2026-03-31 were removed. These are administrative updates and do not alter core trial content such as eligibility, interventions, or outcomes.SummaryDifference0.1%

- Check44 days agoChange DetectedAdministrative updates were made to the Study Record Dates. Two dates were added (2026-04-01 and 2026-03-31) and two were removed (2026-03-25 and 2026-03-24).SummaryDifference0.1%

- Check52 days agoChange DetectedThe page shows new update dates (2026-03-25 and 2026-03-24) and removal of earlier dates (2026-03-18, 2026-03-17), indicating changes to the study record's update history.SummaryDifference0.1%

Stay in the know with updates to Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.